A Study to Learn More About How Well BAY3018250 Works and How Safe it is for People With Proximal Deep Vein Thrombosis

Exclusion Criteria

• •Acute symptomatic pulmonary embolism (PE) requiring systemic or catheter-directed thrombolytic therapy, catheter-directed mechanical thrombectomy, or surgical embolectomy
• •Active bleeding or high risk for bleeding (at the discretion of the investigator)
• •Recent (\<3 months) ischemic stroke, myocardial infarction, intracranial hemorrhage, or major surgery or severe trauma (at the discretion of the investigator)
• •Active cancer, i.e., locally active, regionally invasive or metastatic and/or anticancer therapy within the last 6 months, except basal cell or squamous cell carcinoma
• •Therapeutic-dose anticoagulants for \> 72 hours before randomization, or current use of vitamin K antagonists
• •Planned or current use of the following medications:
• •* Any antiplatelet therapy, except acetylsalicylic acid (ASA) ≤100 mg/day
• •* Antifibrinolytic drugs
• •* Therapeutic antibodies
• •Male participants with women of childbearing potential (WOCBP) partners unwilling to use highly effective contraception from start of study intervention until end of study.